Will it slump to 50 cents?
Here are the factors to which I attribute the current share price decline.
First, there have been virtually no media splashes about CTIX or its technologies.
Experienced investors know this and are going to stay away from CTIX until something definitive comes out.
Let’s face it. CTIX is an over the counter bulletin board stock. OTCBB issues are only for ignorant speculators and day-traders.They don’t understand the company’s technologies or their market potentials.
Big Pharma know they are out there, know they are looking for partners No one wants to take a hugh risk at this point
NASDAQ Listing. Where is it? Personally, I think it better to retain my investment assets for a clearly propitious event
This list includes name of company, stock symbol, and place of incorporation.
A-Power Energy (APWR) (British Virgin Islands)
Advanced Battery Technology (ABAT) (Delaware)
Agfeed Industries (FEED) (Nevada)
American Oriental Bioengineering (AOBI) (Colorado)
AutoChina International (AUTCF) (Cayman Islands)
China Agritech (CAGC) (Delaware)
China Century Dragon Media (CCDM) (Delaware)
China Direct Industries (CDII) (Florida)
China Education Alliance (CEAI) (North Carolina)
China Electric Motors (CELM) (Delaware)
China Energy Savings Technology (CESV) (Nevada)
China Infrastructure Investment (CIIC) (Nevada)
China Integrated Energy (CBEH) (Delaware)
China Intelligent Lighting (CILE) (Delaware)
China MediaExpress (CCME) (Delaware)
China Medicine Corporation (CHME)
China Natural Gas (CHNG) (Delaware)
China North East Petroleum (CNEP) (Nevada)
China Nutrifruit (CNGL) (Nevada)
China Ritar Power (CRTP) (Utah)
China Shenghuo Pharmaceutical (CKUN) (Delaware)
China Sky One Medical (CSKI) (Nevada)
China Valves Technology (CVVT) (Nevada)
China Water & Drinks (HEK) (Nevada)
China-Biotics (CHBT) (Delaware)
ChinaCast Education (CAST) (Delaware)
Deer Consumer Products (DEER) (Nevada)
Duoyuan Global Water (DGWIY) (British Virgin Islands)
Duoyuan Printing (DYNP) (Wyoming)
Fuqi International (FUQI) (Delaware)
HQ Sustainable Maritime (HQSM) (Delaware)
Jiangbo Pharmaceuticals (JGBO) (Florida)
Keyuan Petrochemicals (KEYP) (Nevada)
L&L Energy, Inc. (LLEN) (Delaware)
Lihua International, Inc. (LIWA) (Delaware)
Longtop Financial (LGFTY) (Cayman Islands)
Longwei Petroleum Investment Holding Limited (LPIH)
NIVS IntelliMedia Technology (NIVS) (Delaware)
Orient Paper (ONP) (Nevada)
Orsus Xelent Technologies (ORSX) (Delaware)
Puda Coal (PUDA) (Delaware)
Qiao Xing Mobile Communication (QXMCF) (British Virgin Islands)
Qiao Xing Universal Resources (XINGF) (British Virgin Islands)
RINO International (RINO) (Nevada)
Sino Clean Energy (SCEI) (Nevada)
Sino-Forest Corp. (TSX: TRE) (Ontario)
SinoTech Energy (CTESY) (Cayman Islands)
SinoHub Inc. (SIHI) (Delaware)
Subaye (SBAY) (California)
Tibet Pharmaceutical Inc. (TBET) (British Virgin Island)
Universal Travel Group (UTRA) (Nevada)
Wonder Auto Technology (WATG) (Nevada)
Wuhan General Group (WUHN) (Nevada)
Yuhe International (YUII) (Nevada)
ZST Digital Networks (ZSTN) (Delaware)
Akai Holdings & Grande Holdings
Euro-Asia Agricultural Holdings & Yang Bin
Shanghai Land Holdings & Zhou Zhengyi
% of Shares Held by All Insider and 5% Owners 39%
% of Shares Held by Institutional & Mutual Fund Owners: 0%
Major Direct Holders (Forms 3 & 4)
MENON KRISHNA N/A Aug 28, 2014
EHRLICH LEO 8,585,002 Dec 30, 2014
Top Institutional Holders
Franklin Street Advisors, Inc. 38,000 0.03 98,040 Jun 30, 2015
Top Mutual Fund Holders
Holder % Out
This is the answer who now sells !!!?
I have not short position but still thinking already 5 years.I went through all phases of the beautiful and bankruptcy, so do not magnify see, but see real things.And one of these things is money spent for research.Abnormally small amount!
Nice to live in the clouds that we already live in Polymedix A NEW HOUSE by the OCEAN yes a NEW HOUSE by the OCEAN. And it will. Maybe Monday, maybe last day in Oct. but it will happen. And then we all woke up one day..But obviously and I admit i am not smart enough to know...But there is something amiss here..The fact that the company uses for Research Development only Jun 30, 2015 2,414 $ (All numbers in thousands) it's really a miracle Really a miracle for 3 phase Bril and phase 1 K and....these figures are a miracle really!!! for Research Development only Jun 30, 2015 2,414 $ (All numbers in thousands) in other companies spend so much money on coffee and representation but with us for 3 phase is not a problem and a whole bunch of other studies
I believe only in science and god.
"Rule 10b-5: Employment of Manipulative and Deceptive Practices":
It shall be unlawful for any person, directly or indirectly, by the use of any means or instrumentality of interstate commerce, or of the mails or of any facility of any national securities exchange, (a) To employ any device, scheme, or artifice to defraud,(b) To make any untrue statement of a material fact or to omit to state a material fact necessary in order to make the statements made, in the light of the circumstances under which they were made, not misleading, or(c) To engage in any act, practice, or course of business which operates or would operate as a fraud or deceit upon any person,in connection with the purchase or sale of any security."
The Company’s previously reported mechanism of action (MOA) of Kevetrin strongly suggests that Kevetrin has potential to enhance chemosensitivity. Multiple reports from different laboratories have shown that drugs modulating any of these: p53, HDAC2, c-MYC3(p53:Clin. Can. Research 2009 15, 6495-502; HDAC: Cancer Sci 2008 99, 378-84; c-Myc: Biomed Pharmacother 2015 73, 123-128) has shown enhanced sensitivity to chemotherapeutic drugs. p53 is major determinant of chemosensitivity in humans while mutant p53 proteins can induce drug resistance. Since Kevetrin modulates all of the above molecules, laboratory studies have tested the sensitizing ability in mutant p53 cells and tumors which are refractory to chemotherapeutic agents. The combination of Kevetrin with chemotherapy drugs resulted in synergistic apoptosis at a much lower concentrations than with each agent individually. Thus, Kevetrin holds promise to maximize tumor cell killing when used in combination therapies. Laboratory studies conducted by Cellceutix and at leading institutions on the effects of Kevetrin in combination with approved cancer drugs, including studies against renal cancer, pancreatic cancer, ovarian cancer, glioblastoma and acute myeloid leukemia, have delivered promising data supporting the ability of Kevetrin to enhance chemosensitivity. Additionally, research indicates that Kevetrin is not likely to alter hematological parameters, which would give Cellceutix the opportunity to combine an immunotherapy with Kevetrin for its maximum outcome. In this approach, Cellceutix believes Kevetrin can provide a significant advantage over other drugs in immuno-oncology combination studies.Compound: Brilacidin
Disease: Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
The intravenous formulation of our lead antibiotic candidate, Brilacidin, has the potential to treat a variety of infections, including Acute Bacterial Skin and Skin Structure Infections (“ABSSSI”), caused by drug-sensitive or drug-resistant strains of Staphylococcus aureus, including Methicillin-Resistant Staphylococcus aureus (MRSA), and by other Gram-positive bacteria.
The Phase 2b trial entitled “A Randomized, Double-Blind Study Comparing Three Dosing Regimens of Brilacidin to Daptomycin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)” completed enrollment in August 2014. On October 23, 2014, we announced positive top-line efficacy data from this Phase 2b ABSSSI trial, and on January 5, 2015, we reported the corresponding 95% confidence intervals. In April 2015, safety and efficacy results from this 215-patient study of brilacidin in patients with ABSSSI, were presented at the 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).
In July 2015, at an End-of-Phase 2 Meeting, Cellceutix and FDA discussed data supporting advancement into Phase 3, as well as the basic elements of a brilacidin Phase 3 program in ABSSSI. This is the first Host Defense Protein (HDP) mimic to advance through Phase 2. Because HDP mimics, such as Brilacidin, represent an entirely new class of antibiotics, there is no potential cross-resistance with currently marketed antibiotics, and due to its unique mechanism of action, resistance to Brilacidin is unlikely to develop. For this and other reasons, such as its high activity against methicillin-resistant Staphylococcus aureus (a leading cause of ABSSSI) brilacidin received FDA designation as a Qualified Infectious Disease Product (QIDP) in November 2014. The QIDP designation was established as part of the Generating Antibiotic Incentives Now (GAIN) Act, passed by the U.S. Congress in July 2012, for the purpose of encouraging pharmaceutical companies to develop new antimicrobial drugs to treat serious and life-threatening infections. Receiving QIDP designation means that Brilacidin is now eligible for additional FDA incentives in the approval and marketing path, including Fast Track designation and Priority Review for development and a five-year extension of market exclusivity.
The Phase 3 ABSSSI program would include two Phase 3 ABSSSI studies, as required by FDA Guidance (October 2013). In addition, the first study would include an interim analysis after a portion of the patients has been enrolled. This would provide an early assessment of both safety and efficacy. As part of the agreement, the Company would submit a Pediatric Study Plan (PSP) within 60 days of the End-of-Phase 2 Meeting. The Company is currently evaluating potential Contract Research Organizations (CROs) and clinical sites for the global Phase 3 program.
The most well-paid powerful job or a private jet or three nannies and a $150 m apartment.
Possible professional success.Late last week,James A. Bianco published his latest letter to shareholders.
This year's letter, like most of Biancos' letters, should inspire most companies to change the way they do business.
Specifically, it should inspire companies to do business the way CTIC does business — sacrificing this year's profits to invest in long-term customer loyalty and product opportunities that will create bigger profits next year and for years thereafter (2085 and later).So it's inspiring to see a striking example of success from a company that has never put short-term profits ahead of long-term investment and value creation.
Over the course of its spectacular 17-year history, CTIC has always put customers, and investing for the long-term, first.Therefore ask James A. Bianco all investors to continue to generously invest as large sums of money.
A small, happy life
I would like once again to thank all who believe in me .I cheated on you over 100 times and in the future will be no different.All for one and one for all...James A. Bianco
Dipexium Pharmaceuticals Surpasses Treatment of 50% of Subjects in Pivotal Phase 3 Clinical Trial
If Locilex® win then BRI-204 is concerned.
Wednesday, September 2, 2015 at the Sidoti & Company, LLC Emerging Growth Conference in New York City.
Wednesday, September 9, 2015 at the Rodman & Renshaw 17th Annual Global Investment Conference in New York City.
Everyone is Talking About Cellceutix Corp (OTCMKTS:CTIX)
Cellceutix common stock on the NASDAQ Capital Market
reflection and curiosity:
Trial conducted at 4 sites in U.S.but not in Ukraine, Russia as in PYMX
there is also PMX63-101,PMX63-102,PMX63-103 hm.. interesting.
Serious Adverse Events All Treated/Safety Population
-Dental abscess left side
-Left side with facial cellulitis
-Worsening primary ABSSSI right leg cellulitis
ECCMID 2015 Copenhagen, Denmark 25 – 28 April 2015
A Randomized, Double-Blind Study Comparing Single-Dose and Short-Course Brilacidin to Daptomycin in the Treatment of Acute Bacterial Skin & Skin Structure Infections (ABSSSI)
Extracts are, for those who do not know !
Brilacidin is a potent anti-staphylococcal compound, with high activity vs. MRSA
•Single-dose brilacidin was effective in a phase 2b ABSSSI study
•Efficacy rates were--
•High across all brilacidin treatment groups, including both single-dose regimens
•High in all analysis populations, including microbiologically evaluable populations
•High at early FDA timepoint (Day 2-3), indicating immediate clinical response
•High at later EMA timepoints (Days 7-8; 10-14), indicating a sustained clinical response
•Similar to 7 days of active comparator (daptomycin)
•PK/PD model correctly predicted high efficacy using single doses
Single-dose brilacidin was safe and well tolerated in a phase 2b ABSSSI study
•Reduction in total dose decreases the frequency, severity, and duration of adverse events, vs. phase 2a study
•Blood pressure events low in 0.6 mg/kg single-dose regimen, similar to or better than daptomycin (active control)
•There were no treatment-related SAEs or hypertension-related SAEs
•Numbness/Tingling mild, transient, and decreased in frequency and severity, vs. phase 2a study
•PK/PD model correctly predicted decrease in AEs with lower total dose, particularly low single-dose regimens
When i look CTIX after PYMX I promised myself I would never buy junk stocks again. So the question is, would expected good news be good enough to keep CTIX's stock from sliding back or even help it gain before the raise? Is the news that good?
I was just wondering if anyone has an explanation as to why this company is very much under the radar
Form SC 13G it is empty, why!?Maybe its time for CTIX to get listed on the Nasdaq..it will open them up to lots of funds that cannot buy OTC stocks.
So, is the good news good enough? Do you feel lucky?
Investigation over Possible Violations of Securities Laws
An investigation for investors in Cellceutix Corp (OTCMKTS:CTIX) shares over potential securities laws violations by Cellceutix was announced and OTCMKTS:CTIX stockholders should contact the Shareholders Foundation.An investigation on behalf of investors of Cellceutix Corp (OTCMKTS:CTIX) shares over potential securities laws violations by Cellceutix and certain of its directors and officers in connection certain financial statements was announced.
Investors who purchased shares of Cellceutix Corp (OTCMKTS:CTIX), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation or call 858-779-1554.
What is this naw!